The global systemic scleroderma treatment market size is expected to reach USD 1.9 billion by 2027, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 4.0% from 2020 to 2027. The market is largely attributable to the strong presence of therapies used off-label that include small molecule therapies including branded, generics, and OTC drugs.
The mix of several indications and drug classes engenders a fragmented space with multiple players. Johnson and Johnson Services, Inc. dominated the market with a share of 23.7% in the year 2019. United Therapeutics Corporation is the second biggest service provider in the space with a significant share in 2019. The other players such as F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, and Pfizer Inc. also have a significant share of the global market.
The on-label treatment is in the development phase. Major players with therapies undergoing clinical development are divided into two sorts. There are some developing new compounds, whereas certain other established players are seen repurposing their drugs (currently approved for other indications) for scleroderma use. In September 2019, Boehringer Ingelheim GmbH announced the U.S. FDA approval of Ofev for the treatment of interstitial lung disease in patients with systemic sclerosis.
For PDF sample Copy or More Details please visit link @: https://www.grandviewresearch.com/industry-analysis/systemic-scleroderma-treatment-market
Supplemental indication approval is one of the most common strategies adopted by pharmaceutical players thriving in the space. There are several pharmaceutical companies adopting strategies that favor the pharmaceutical industry in offsetting high development costs.
For instance, companies are developing promising product candidates such as Ziritaxestat, an autotaxin inhibitor from Galapagos NV in collaboration with Gilead Sciences, Inc. Furthermore, Horizon Therapeutics plc entered the space with the acquisition of Curzion Pharmaceuticals, Inc. in April 2020 that is developing HZN-825 and Tepezza.
Systemic Scleroderma Treatment Market Report Highlights
• The immunosuppressors segment held the largest revenue share in 2019, followed by prostacyclin analogues
• The high preference for immunosuppressants owing to the favorable reimbursement scenario associated with this drug class will support its dominant share in this space
• The U.S. held the majority of the revenue share in 2019. Expected label expansions and the expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs are expected to support market growth
• Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma
To request research report sample copy with TOC please visit @: Systemic Scleroderma Treatment Market Report, 2020-2027 (grandviewresearch.com)
Systemic Scleroderma Treatment Market Segmentation
Grand View Research has segmented the global systemic scleroderma treatment market based on drug class and region:
Systemic Scleroderma Treatment Drug Class Outlook (Revenue, USD Million, 2016 - 2027)
• Immunosuppressors
• Phosphodiesterase 5 inhibitors - PHA
• Endothelin Receptor Antagonists
• Prostacyclin Analogues
• Calcium Channel Blockers
• Others
Systemic Scleroderma Treatment Regional Outlook (Revenue, USD Million, 2016 - 2027)
• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
• Asia Pacific
o China
o Japan
o India
o Australia
• Latin America
o Brazil
o Argentina
o Mexico
• MEA
o South Africa
o Saudi Arabia
o UAE
List of Key Players of Systemic Scleroderma Treatment Market
• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Novartis AG
• Pfizer Inc.
• Bayer AG
For Inquire before buying please visit @: Inquiry before buying Grand View Research San Francisco California
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.